B. Laguerre

发表

Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy

K. Bensalah, N. Rioux-Leclercq, A. Ravaud, 2017, Targeted Oncology.

Safety and Efficacy of Sorafenib in Renal Cell Carcinoma

K. Bensalah, N. Rioux-Leclercq, C. Vigneau, 2012 .

Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge

P. Kerbrat, B. Laguerre, H. Mesbah, 2010, Cancer Chemotherapy and Pharmacology.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

S. Culine, J. Hainsworth, R. Huddart, 2017, The Lancet.

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.

S. Culine, N. Salem, M. Baciuchka, 2016, International journal of radiation oncology, biology, physics.

Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.

G. Gravis, F. Joly, P. Barthélémy, 2021, European journal of cancer.

Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.

S. Richard, G. De Velasco, J. Scoazec, 2021, European journal of cancer.

All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.

N. Rioux-Leclercq, J. Goujon, C. Vigneau, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

A. Ravaud, S. Culine, J. Machiels, 2017, European urology.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

J. Patard, A. Ravaud, R. Motzer, 2018, European urology.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

S. Culine, G. Deplanque, S. Oudard, 2016, European urology.

[Place of surgery before and after concurrent chemoradiotherapy for locally advanced cervical carcinoma: A retrospective study of 102 cases].

V. Lavoué, B. Laguerre, H. Mesbah, 2011, Journal de gynecologie, obstetrique et biologie de la reproduction.

Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib’s Toxicities in Hepatocellular Carcinoma

A. Guillygomarc’h, A. Brunot, B. Laguerre, 2017, Cancer nursing.

Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients

F. Joly, J. Malhaire, E. Voog, 2020, International journal of cancer.

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

J. Carles, B. Tombal, F. Calabrò, 2022, The Lancet.

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.

D. Spaeth, S. Oudard, P. Barthélémy, 2018, European urology oncology.

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

S. Oudard, G. Gravis, N. Houédé, 2015, BMC Cancer.

Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.

G. Calais, P. Garaud, P. Pommier, 2010, International journal of radiation oncology, biology, physics.

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.

D. Spaeth, S. Oudard, M. Krainer, 2018, European journal of cancer.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

S. Culine, S. Oudard, G. Gravis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

B. Escudier, F. Joly, B. Laguerre, 2017, BMC Cancer.

Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

B. Escudier, S. Oudard, G. Gravis, 2022, Clinical genitourinary cancer.

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

J. Bourhis, C. Sire, A. Aupérin, 2021, The Lancet. Oncology.

Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study

K. Bensalah, J. Patard, J. Bernhard, 2018, BJU international.

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

B. Duclos, S. Oudard, G. Gravis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

A. Ravaud, J. Machiels, G. Deplanque, 2015, European urology.

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

C. Porta, A. Ravaud, S. Lheureux, 2019, European urology oncology.

Comprehensive study of nine novel cases of TFEB‐amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression

K. Bensalah, N. Rioux-Leclercq, E. Compérat, 2022, Histopathology.

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

S. Culine, Y. Allory, W. Hilgers, 2021, Clinical genitourinary cancer.

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

S. Culine, Y. Allory, G. Gravis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Patho

S. Culine, Y. Allory, G. Gravis, 2020, European urology.

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.

J. Shamash, P. Hutton, O. Ståhl, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma

R. Huddart, J. Shamash, O. Ståhl, 2015 .

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.

A. Tafreshi, J. Carles, S. Oudard, 2022, European urology.

The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

S. Culine, G. Gravis, P. Barthélémy, 2022, European urology.

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

S. Culine, G. Gravis, N. Houédé, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

An Anusual Cause of Secondary Hypertension in a Young Man

N. Rioux-Leclercq, C. Vigneau, B. Laguerre, 2015 .

Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma

K. Bensalah, J. Patard, A. Ravaud, 2018, The New England journal of medicine.

Is home blood pressure monitoring feasible and well accepted in nephrectomized patients for renal cancer? (STAFF study)

E. Oger, E. Donal, A. Lafourcade, 2015, Blood pressure.

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

S. Culine, Y. Allory, S. Oudard, 2019, Clinical genitourinary cancer.

Individual adaptive dosing of topotecan in ovarian cancer.

S. Culine, F. Pinguet, P. Canal, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin‐13

P. Ferrara, D. Caput, F. Quintin-Colonna, 1995, European journal of immunology.

Independent association of PD‐L1 expression with noninactivated VHL clear cell renal cell carcinoma—A finding with therapeutic potential

K. Bensalah, N. Rioux-Leclercq, J. Patard, 2017, International journal of cancer.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

A. Ravaud, R. Motzer, M. Casey, 2018, Clinical Cancer Research.

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.

L. Appleman, G. Gravis, E. Yu, 2022, European urology.

Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.

D. Harrison, N. Salem, N. Vasudev, 2016, Urologic oncology.

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.

B. Escudier, S. Oudard, G. Gravis, 2020, European journal of cancer.

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

David Pérol, Sylvie Négrier, J. Bay, 2011, The Lancet. Oncology.

KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

A. Tafreshi, J. Bono, S. Oudard, 2020 .

Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib

N. Rioux-Leclercq, D. Lambrechts, J. Zucman‐Rossi, 2020 .

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG).

A. Ravaud, S. Culine, B. Escudier, 2015 .

625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update

L. Appleman, G. Gravis, E. Yu, 2020 .

KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

L. Appleman, G. Gravis, E. Yu, 2019 .

A Nomogram to predict parotid gland overdose in head and neck IMRT

R. Crevoisier, P. Haigron, A. Simon, 2016, Radiation oncology.

Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma

S. Culine, G. Gravis, N. Houédé, 2016, BJU international.

Immunotherapy in Renal Cell Carcinoma: The Future Is Now

K. Bensalah, N. Rioux-Leclercq, B. Peyronnet, 2020, International journal of molecular sciences.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

A. Ravaud, S. Culine, G. Deplanque, 2015, The Lancet. Oncology.

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study

S. Oudard, P. Barthélémy, C. Vicier, 2022, Cancers.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

K. Bensalah, N. Rioux-Leclercq, R. Mathieu, 2019, International journal of molecular sciences.

Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting

N. Rioux-Leclercq, J. Zucman‐Rossi, E. Lerut, 2017, Clinical genitourinary cancer.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

J. Patard, A. Ravaud, R. Motzer, 2016, The New England journal of medicine.

Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.

N. Rioux-Leclercq, M. Baldewijns, E. Lerut, 2020, Urologic oncology.

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.

C. Tournigand, K. Bensalah, J. Bernhard, 2022, The Lancet. Oncology.

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).

N. Rioux-Leclercq, F. Goldwasser, B. Escudier, 2021, European journal of cancer.

Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.

K. Bensalah, N. Rioux-Leclercq, A. Ravaud, 2019, Clinical Genitourinary Cancer.

Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial.

E. Blot, V. Girre, E. Brain, 2011, Critical reviews in oncology/hematology.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

A. Ravaud, J. Machiels, B. Esterni, 2013, The Lancet. Oncology.

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

A. Ravaud, S. Culine, G. Deplanque, 2012, European journal of cancer.

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.

A. Ravaud, S. Culine, G. Le Teuff, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.

D. Spaeth, S. Oudard, P. Barthélémy, 2019, European journal of cancer.

Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

K. Bensalah, A. Ravaud, J. Bernhard, 2021, European urology.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study

A. Ravaud, R. Motzer, M. Casey, 2018, Clinical Cancer Research.

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

B. Escudier, F. Joly, B. Laguerre, 2017, BMC Cancer.

Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial.

B. Escudier, S. Oudard, G. Gravis, 2020 .

[The neutrophil gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal cell carcinoma].

N. Rioux-Leclercq, J. Patard, S. Théoleyre, 2011, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

A. Ravaud, S. Culine, B. Escudier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

E. Raymond, X. Pivot, J. Armand, 2001, British Journal of Cancer.

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).

B. Esterni, F. Joly, F. Retornaz, 2010, Critical reviews in oncology/hematology.

UFT plus oral calcium folinate/vinorelbine for advanced breast cancer.

P. Fumoleau, P. Kerbrat, B. Laguerre, 1999, Oncology.

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

J. Bourhis, C. Borel, P. Maingon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

S. Culine, Y. Allory, G. Gravis, 2023, Cancers.

A PET-based nomogram for oropharyngeal cancers.

J Castelli, A Depeursinge, John O. Prior, 2017, European journal of cancer.

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

A. Ravaud, J. Machiels, B. Esterni, 2014, European journal of cancer.

An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response.

S. Culine, S. Oudard, G. Gravis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.

B. Escudier, S. Oudard, G. Gravis, 2019, Journal of Clinical Oncology.

Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.

G. Deplanque, S. Oudard, G. Gravis, 2015 .

Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.

S. Culine, G. Gravis, Anne-Laure Martin, 2014 .

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Very long-term complete remission can be achieved in men with high-risk localized prostate cancer and a very high PSA value: an analysis of the GETUG 12 Phase 3 trial

S. Culine, D. Drubay, G. Deplanque, 2023, Clinical Genitourinary Cancer.

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

A. Fourrier-Réglat, F. Tubach, J. Prevost, 2019, British Journal of Cancer.

Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).

Y. Allory, S. Oudard, G. Gravis, 2023, European journal of cancer.

LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial

C. Tournigand, J. Zucman‐Rossi, C. Sautès-Fridman, 2020 .

724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)

Y. Allory, S. Oudard, G. Gravis, 2020 .

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

S. Oudard, M. Baciuchka, M. Laramas, 2016, European journal of cancer.

Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer

K. Bensalah, N. Rioux-Leclercq, F. Guillé, 2016, International journal of urology : official journal of the Japanese Urological Association.

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer

P. Barthélémy, B. Laguerre, C. Helissey, 2021, Cancer medicine.

73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis

J. Carles, J. Bono, S. Oudard, 2021, Annals of Oncology.

Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.

J. Bono, L. Appleman, G. Gravis, 2020 .

Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

J. Bono, L. Appleman, G. Gravis, 2020 .

Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept

K. Bensalah, N. Rioux-Leclercq, S. Shariat, 2020, World Journal of Urology.

Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma

N. Rioux-Leclercq, J. Patard, J. Zucman‐Rossi, 2017, Acta oncologica.

Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.

S. Culine, B. Escudier, S. Oudard, 2021, European urology.

Population pharmacokinetics of topotecan: intraindividual variability in total drug

S. Culine, F. Pinguet, P. Canal, 2000, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.

B. Escudier, S. Oudard, G. Gravis, 2023, European journal of cancer.

Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathol

S. Culine, Y. Allory, G. Gravis, 2020 .

Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.

C. Tournigand, C. Sautès-Fridman, W. Fridman, 2023, Journal of Clinical Oncology.

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial.

F. Joly, S. Ladoire, R. Flippot, 2018, Annals of Oncology.

Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.

G. Gravis, S. Chabaud, C. Chevreau, 2017 .

Real-world data of cabozantinib in patients with VEGF-refractory metastatic renal cell carcinoma (mRCC): Results from the French Early Access Program (CABOREAL).

B. Escudier, S. Oudard, G. Gravis, 2020 .

NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).

N. Rioux-Leclercq, C. Sautès-Fridman, N. Chaput, 2020 .

Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma.

K. Bensalah, J. Patard, S. Culine, 2009, European urology.

mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.

B. Duclos, F. Joly, P. Barthélémy, 2013, Critical reviews in oncology/hematology.

PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).

F. Bidault, C. Borel, V. Costes, 2016 .

Synchronous Metastatic Clear‐Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype

K. Bensalah, N. Rioux-Leclercq, J. Mosser, 2017, Clinical genitourinary cancer.

PDL-1 and PDL1 expressions in clear cell renal cell carcinoma (ccRCC) of metastatic patients with sunitinib first-line treatment.

K. Bensalah, N. Rioux-Leclercq, A. Ravaud, 2015 .

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

R. Huddart, S. Park, J. Ku, 2023, Journal of Clinical Oncology.

A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC).

D. Lambrechts, J. Zucman‐Rossi, R. Paridaens, 2012, Journal of Clinical Oncology.

A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC).

D. Lambrechts, J. Zucman‐Rossi, R. Paridaens, 2012, Journal of Clinical Oncology.

Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma

B. Escudier, S. Oudard, P. Barthélémy, 2019, Annals of Oncology.

Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.

K. Bensalah, N. Rioux-Leclercq, A. Ravaud, 2017, Urologic oncology.

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

A. Ravaud, S. Culine, B. Escudier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

J. Bourhis, C. Borel, P. Maingon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.

F. Bidault, B. Escudier, S. Oudard, 2016, Clinical genitourinary cancer.

Improving the pre-screening of eligible patients in order to increase enrollment in cancer clinical trials

Boris Campillo-Gimenez, Marc Cuggia, Oussama Zekri, 2015, Trials.

[Post-treatment follow-up of breast cancer patients: comments on the guidelines of the American Society of Clinical Oncology (ASCO)].

P. Kerbrat, B. Laguerre, C. Lefeuvre, 1997, Bulletin du cancer.

612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

A. Tafreshi, S. Oudard, G. Gravis, 2021, Annals of Oncology.